Medical/Pharmaceuticals
Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
* Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product * Phase I and II clinical trials completed. Phase III to be done in co-development with global partners. * Unique, Australian developed unique Patchless Patch™ delivery technolo...
2026-04-28 14:25
3675
BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE
Key Highlights: * An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues...
2026-04-28 10:17
4928
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
TOKYO, April 28, 2026 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, susta...
2026-04-28 09:00
5209
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA[1]-targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating pros...
2026-04-28 07:44
6316
Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted reg...
2026-04-27 23:19
5244
The EXCEL - First-of-its-kind study highlights critical role of essential phospholipids in improving Fatty Liver Disease
PARIS, April 27, 2026 /PRNewswire/ -- A new study has established that treatment with essential phospholipids (Essentiale) resulted in a 2.5 times greater reduction in liver fat, significant improvement in fatigue and improvement of glycaemic control in individuals with Metabolic dysfunction–Ass...
2026-04-27 23:18
5636
CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026
LONDON, April 27, 2026 /PRNewswire/ -- Concept Medical Inc.
2026-04-27 23:17
4424
Sarawak Secures Landmark Win to Host APAC's Leading Lung Disease Conference in 2028
KUCHING, Malaysia, April 27, 2026 /PRNewswire/ -- Sarawak has won hosting rights for the 11th Asia Pacific Regional Conference 2028 (APRC 2028) of the International Union Against Tuberculosis and Lung Disease, marking a significant milestone in the destination's continued rise as the legacy capit...
2026-04-27 22:11
4626
IMG Pharma Enters into Definitive Agreement to Acquire Matsumoto Pharmaceutical
TOKYO, April 27, 2026 /PRNewswire/ -- IMG Pharmaceutical Co., Ltd. ("IMG Pharma"), a majority-owned subsidiary of IMG Japan, the Group's holding company, announced that it has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co., Ltd., a Japanese pharmaceutical manufacturer...
2026-04-27 16:35
4069
Eyebright Medical Releases Its 2025 Annual Report and Sustainability Report
Innovation Drives Strong Results, While Global Expansion and ESG Practices Progress Steadily HONG KONG, April 27, 2026 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", "the Company", Stock Code: 688050.SH, together with its subsidiaries collectively ref...
2026-04-27 09:00
4534
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 27, 2026 /PRN...
2026-04-27 08:10
7491
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findi...
2026-04-26 19:00
8271
Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
* High Impact Session presented at Heart Rhythm Society's Congress in Chicago * First time showing results of new Less Invasive approach * Improvement in Left Ventricular Ejection Fraction (LVEF), 6 Minute Walk Test (6MWT), Quality of Life (QOL) and New York Heart Association (NYHA) class. C...
2026-04-25 04:00
4322
MALAYSIA HEALTHCARE RETURNS TO MEDAN AS INDONESIAN PATIENTS SEEK TRUSTED SECOND OPINIONS ABROAD
MEDAN, Indonesia, April 25, 2026 /PRNewswire/ -- Malaysia has steadily emerged as one of the most trusted destinations for Indonesian patients seeking timely and reliable care. Following its last major outreach in 2022, Malaysia Healthcare returns to Medan this year, reconnecting with a community...
2026-04-25 02:10
6470
Quasar Medical Celebrates Grand Opening of New Manufacturing Facility in Thailand
The new Chonburi facility increases global manufacturing capacity and strengthens regional supply chain capabilities for leading MedTech customers CHONBURI, Thailand, April 24, 2026 /PRNewswire/ -- Quasar Medical, a global leader in the manufacturing of interventional and minimally invasive medic...
2026-04-24 20:30
3263
Award-Winning XERF™ The Structural Skin Tightening Device, Now Available in Singapore
Cynosure Lutronic's non-invasive facial lifting and tightening device XERF™, recognised at the SBR Technology Excellence Awards 2026 is now offered at aesthetic clinics across Singapore. SINGAPORE, April 23, 2026 /PRNewswire/ -- Patients in Singapore now have access to XERF™, Cynosure Lutronic's...
2026-04-24 13:08
4466
Daewoong Pharmaceutical Hosts 'NABOTA Master Class'… Highlighting Safety Amid Growing Demand for High-Dose, Repetitive Treatments
* 74 healthcare professionals from 13 countries attended, recognizing the value of PrabotulinumtoxinA's "Safety" * Comprehensive program including anatomy sessions, proprietary injection techniques, and 1:1 hands-on training * Global participants praise the program as "a platform to share pr...
2026-04-24 11:16
5585
EVERISE NAMED LEADER IN EVEREST GROUP'S HEALTHCARE CUSTOMER EXPERIENCE MANAGEMENT PEAK MATRIX® 2026
PLANTATION, Fla., April 23, 2026 /PRNewswire/ -- Leading global healthcare customer experience provider Everise today announced that it has been named a Leader in Everest Group's Healthcare Customer Experience Management (CXM) Intelligent Operations PEAK Matrix® Assessment 2026 for the first time...
2026-04-23 21:00
3371
Servier completes the acquisition of Day One Biopharmaceuticals
* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs. * Transaction represents total equity ...
2026-04-23 20:30
4247
Published Clinical Study Illustrates Benefits of Promentum® Recover as Low-Dose Solution for Post Exercise Recovery
MOMENCE, Ill., April 23, 2026 /PRNewswire/ -- A recently published human
clinical study
2026-04-23 20:00
3678
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 263 media titles]
2026-10-05 11:51Most Read
RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS
2026-10-04 00:56
10600
Nuix Neo Generative AI Framework
2026-10-08 08:02
9072
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8074
